Aegerion Pharmaceuticals, Inc. — Net Income by Fiscal Year
11 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/5ecfab77-d71e-43f8-baec-f582de6e630c/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2015 | $-73.3M | 2015-01-01 – 2015-12-31 | evidence 0001558370-16-004149 |
| FY 2014 | $-39.4M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-073654 |
| FY 2013 | $-63.4M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-079791 |
| FY 2012 | $-62.3M | 2012-01-01 – 2012-12-31 | evidence 0001193125-13-112185 |
| FY 2011 | $-130.4M | 2005-02-04 – 2012-03-31 | evidence 0001193125-12-224870 |
| FY 2010 | $-14.3M | 2010-01-01 – 2010-12-31 | evidence 0001193125-13-112185 |
| FY 2009 | $-12.2M | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-117291 |
| FY 2008 | $-25.0M | 2008-01-01 – 2008-12-31 | evidence 0001193125-12-117291 |
| FY 2007 | $-20.2M | 2007-01-01 – 2007-12-31 | evidence 0001193125-12-117291 |
| FY 2006 | $-6.2M | 2006-01-01 – 2006-12-31 | evidence 0001193125-12-117291 |
| FY 2005 | $-1.4M | 2005-02-05 – 2005-12-31 | evidence 0001193125-12-117291 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Aegerion Pharmaceuticals, Inc. — all facts · Revenue · Operating Income